A Chinese healthcare platform has started selling Pfizer’s oral COVID-19 treatment Paxlovid in what appears to be the first retail sale of the drug in the country, as China braces for a surge in COVID patients.
About the Author
A Chinese healthcare platform has started selling Pfizer’s oral COVID-19 treatment Paxlovid in what appears to be the first retail sale of the drug in the country, as China braces for a surge in COVID patients.
